These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26196012)

  • 1. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.
    Santegoets SJ; Stam AG; Lougheed SM; Gall H; Jooss K; Sacks N; Hege K; Lowy I; Scheper RJ; Gerritsen WR; van den Eertwegh AJ; de Gruijl TD
    J Immunother Cancer; 2014; 2():31. PubMed ID: 26196012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
    Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
    Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells.
    van Dodewaard-de Jong JM; Santegoets SJ; van de Ven PM; Versluis J; Verheul HM; de Gruijl TD; Gerritsen WR; van den Eertwegh AJ
    Oncoimmunology; 2016 Apr; 5(4):e1105431. PubMed ID: 27141390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
    Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
    Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity.
    Karan D; Van Veldhuizen P
    Immunotherapy; 2012 Jun; 4(6):577-80. PubMed ID: 22788125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
    Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
    J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
    Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P
    Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.
    De Remigis A; de Gruijl TD; Uram JN; Tzou SC; Iwama S; Talor MV; Armstrong TD; Santegoets SJ; Slovin SF; Zheng L; Laheru DA; Jaffee EM; Gerritsen WR; van den Eertwegh AJ; Le DT; Caturegli P
    Int J Cancer; 2015 Jan; 136(1):127-37. PubMed ID: 24832153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.
    Lipson EJ; Sharfman WH; Chen S; McMiller TL; Pritchard TS; Salas JT; Sartorius-Mergenthaler S; Freed I; Ravi S; Wang H; Luber B; Sproul JD; Taube JM; Pardoll DM; Topalian SL
    J Transl Med; 2015 Jul; 13():214. PubMed ID: 26143264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.
    Santegoets SJAM; de Groot AF; Dijkgraaf EM; Simões AMC; van der Noord VE; van Ham JJ; Welters MJP; Kroep JR; van der Burg SH
    Oncoimmunology; 2018; 7(8):e1465166. PubMed ID: 30221063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Miscarriage Is Associated With Dysregulations in Peripheral Blood-Derived Myeloid Dendritic Cell Subsets.
    Ehrentraut S; Sauss K; Neumeister R; Luley L; Oettel A; Fettke F; Costa SD; Langwisch S; Zenclussen AC; Schumacher A
    Front Immunol; 2019; 10():2440. PubMed ID: 31681319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines.
    Poschke I; Mao Y; Adamson L; Salazar-Onfray F; Masucci G; Kiessling R
    Cancer Immunol Immunother; 2012 Jun; 61(6):827-38. PubMed ID: 22080405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
    J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
    Li J; Srivastava RM; Ettyreddy A; Ferris RL
    J Immunother Cancer; 2015; 3():54. PubMed ID: 26579227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.
    Kitano S; Postow MA; Ziegler CG; Kuk D; Panageas KS; Cortez C; Rasalan T; Adamow M; Yuan J; Wong P; Altan-Bonnet G; Wolchok JD; Lesokhin AM
    Cancer Immunol Res; 2014 Aug; 2(8):812-21. PubMed ID: 24844912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
    Simons JW; Sacks N
    Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.
    Brimnes MK; Vangsted AJ; Knudsen LM; Gimsing P; Gang AO; Johnsen HE; Svane IM
    Scand J Immunol; 2010 Dec; 72(6):540-7. PubMed ID: 21044128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.